Search
Rocaglamide
go.drugbank.com/drugs/DB15495ExperimentalRocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides. … [didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of
Clodronic acid
go.drugbank.com/drugs/DB00720ApprovedInvestigationalVet approvedClodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has de...
Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnMafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. In 1998, mafenide acetate was approved under the F...
Paromomycin
go.drugbank.com/drugs/DB01421ApprovedInvestigationalAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
go.drugbank.com/drugs/DB11331ApprovedWithdrawnPalmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].
G207
go.drugbank.com/drugs/DB05827InvestigationalThese viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. … MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.
Ouabain
go.drugbank.com/drugs/DB01092ApprovedIt is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
Tazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigational[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Brodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions.